Skip to main content
W.-K. Hofmann on Muck Rack

W.-K. Hofmann

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with W.-K.

Contact W.-K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

|
By P. Panayiotidis, J. H. Richter, D. Nowak, P. Ljungman, T. H. Brümmendorf, W. Majeed, S. Rinaldetti, M. Chepeleva, A. Hedblom, C. Sticht, M. Muciek, U. Olsson-Strömberg, V. Nowak, N. von Bubnoff, K. Lotfi, L. Stenke, H. Hjorth-Hansen, T. Gedde-Dahl, A. Burchert, P. V. Nazarov, E. Felde, I. Tarnopolscaia, C. Hoelting, A. Fabarius, W.-K. Hofmann, F.-X. Mahon, S. Saussele, M. Pfirrmann
| Nature Verified
Abstract The European Stop Kinase Inhibitors (EURO-SKI) trial was launched to investigate the discontinuation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML). The molecular mechanisms underlying sustained treatment-free remission (TFR) and loss of TFR, are still poorly understood. To address this, we performed whole transcriptome gene expression analyses coupled with NanoString nCounter-based absolute gene quantification.
Open in Who Shared Issue with article?
See all 1 articles